SCHEMBL3494129

SCHEMBL3494129

COc1cccc(-c2coc3ccccc3c2=O)c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.73
SMN1; SMN2 Q16637 6/20 0.73
MEN1 O00255 5/20 0.73
KMT2A Q03164 5/20 0.73
PPARG P37231 2/20 0.73
PPARD Q03181 2/20 0.73
PPARA Q07869 2/20 0.73
KDM4E B2RXH2 4/20 0.69
TP53 P04637 4/20 0.69
CYP3A4 P08684 4/20 0.69
HPGD P15428 4/20 0.69
NPC1 O15118 4/20 0.69
RAB9A P51151 4/20 0.69
ALDH1A1 P00352 4/20 0.69
CYP2D6 P10635 2/20 0.57
CYP2C9 P11712 2/20 0.57
CYP2C19 P33261 2/20 0.57
MAPK1 P28482 2/20 0.57
TSHR P16473 1/20 0.57
ALOX12 P18054 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30527861 0.89 MAPT (0.82) MAPTSMN1; SMN2MEN1KMT2APPARG
SCHEMBL5504492 0.89 MAPT (0.82) MAPTSMN1; SMN2MEN1KMT2APPARG
SCHEMBL2070726 0.84 PPARG (1.00) MAPTSMN1; SMN2MEN1KMT2APPARG
SCHEMBL73754 0.84 ALDH1A1 (0.70) MAPTSMN1; SMN2MEN1KMT2AKDM4E
SCHEMBL30527851 0.84 MAPT (0.70) MAPTSMN1; SMN2MEN1KMT2APPARG
SCHEMBL29085509 0.84 MAPT (0.70) MAPTSMN1; SMN2MEN1KMT2APPARG
SCHEMBL28429116 0.83 MIF (0.56) MAPTSMN1; SMN2MEN1KMT2APPARG
SCHEMBL18312233 0.82 MAPT (0.61) MAPTSMN1; SMN2MEN1KMT2APPARG
SCHEMBL29068825 0.82 MAPT (0.80) MAPTSMN1; SMN2MEN1KMT2APPARG
SCHEMBL762092 0.82 MAPT (1.00) MAPTSMN1; SMN2MEN1KMT2APPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8742141-B2 Inhibition and treatment of prostate cancer metastasis NORTHWESTERN UNIVERSITY (US) 2014-06-03 US disclosed
US-8742141-B2 Inhibition and treatment of prostate cancer metastasis NORTHWESTERN UNIVERSITY (US) 2014-06-03 US disclosed
US-8742141-B2 Inhibition and treatment of prostate cancer metastasis NORTHWESTERN UNIVERSITY (US) 2014-06-03 US disclosed
US-20130296582-A1 INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2013-11-07 US disclosed
US-20130296582-A1 INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2013-11-07 US disclosed
US-20130296582-A1 INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2013-11-07 US disclosed
US-8481760-B2 Inhibition and treatment of prostate cancer metastasis NORTHWESTERN UNIVERSITY (US) 2013-07-09 US disclosed
US-8481760-B2 Inhibition and treatment of prostate cancer metastasis NORTHWESTERN UNIVERSITY (US) 2013-07-09 US disclosed
US-8481760-B2 Inhibition and treatment of prostate cancer metastasis NORTHWESTERN UNIVERSITY (US) 2013-07-09 US disclosed
US-20120283313-A1 INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS NORTHWESTERN UNIVERSITY (US) 2012-11-08 US disclosed
US-20120283313-A1 INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS NORTHWESTERN UNIVERSITY (US) 2012-11-08 US disclosed
WO-2010042933-A9 INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS NORTHWESTERN UNIVERSITY (US) 2010-07-08 WO disclosed
US-20100137425-A1 INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS NORTHWESTERN UNIVERSITY (US) 2010-06-03 US disclosed
US-20100137425-A1 INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS NORTHWESTERN UNIVERSITY (US) 2010-06-03 US disclosed
US-20100137425-A1 INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS NORTHWESTERN UNIVERSITY (US) 2010-06-03 US disclosed
WO-2010042933-A2 INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS NORTHWESTERN UNIVERSITY (US) 2010-04-15 WO disclosed
US-20090124569-A1 INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS NORTHWESTERN UNIVERSITY (US) 2009-05-14 US disclosed
US-20090124569-A1 INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS NORTHWESTERN UNIVERSITY (US) 2009-05-14 US disclosed
US-20090124569-A1 INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS NORTHWESTERN UNIVERSITY (US) 2009-05-14 US disclosed
WO-2009049214-A2 INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS NORTHWESTERN UNIVERSITY (US) 2009-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130296582-A1 INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS MAPK4, MAP4K4, MAP3K4 MAPT 2493/4885SMN1; SMN2 4692/4885MEN1 302/4885
US-20120283313-A1 INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS MAPK4, MAP4K4, MAP3K4 MAPT 2493/4885SMN1; SMN2 4692/4885MEN1 302/4885
US-20090124569-A1 INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS MAPK4, MAP4K4, MAP3K4 MAPT 2493/4885SMN1; SMN2 4692/4885MEN1 302/4885
US-20100137425-A1 INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS MAPK4, MAP4K4, MAP3K4 MAPT 2493/4885SMN1; SMN2 4692/4885MEN1 302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.